

Journal Pre-proof

Trypanocidal and cell swelling activity of 20-deoxysalinomycin

Dietmar Steverding, Daniel Strand, Adam Huczyński

PII: S0014-4894(22)00208-9

DOI: <https://doi.org/10.1016/j.exppara.2022.108414>

Reference: YEXPR 108414

To appear in: *Experimental Parasitology*

Received Date: 5 September 2022


Revised Date: 12 October 2022

Accepted Date: 18 October 2022

Please cite this article as: Steverding, D., Strand, D., Huczyński, A., Trypanocidal and cell swelling activity of 20-deoxysalinomycin, *Experimental Parasitology* (2022), doi: <https://doi.org/10.1016/j.exppara.2022.108414>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc.



CRedit author statement

Dietmar Steverding: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data curation, Writing – Original draft, Visualization. **Daniel Strand:** Methodology, Validation, Investigation, Recourses, Writing – Review and Editing, Funding acquisition; **Adam Huczynski:** Conceptualization, Resources, Writing – Review and Editing.

Journal Pre-proof

1 Trypanocidal and cell swelling activity of 20-
2 deoxysalinomycin

3

4 Dietmar Steverding^{a,*}, Daniel Strand^b, Adam Huczyński^c

5

6 ^a *Bob Champion Research & Education Building, Norwich Medical School, University of*
7 *East Anglia, Norwich, U.K.*

8 ^b *Centre for Analysis and Synthesis, Department of Chemistry, Lund University, Lund,*
9 *Sweden*

10 ^c *Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University,*
11 *Poznań, Poland*

12

13

14 * Corresponding authors.

15 *E-mail address: d.steverding@uea.ac.uk*

16

17

18 A B S T R A C T

19 The naturally occurring polyether ionophore salinomycin was previously found to display
20 promising anti-proliferative activity against bloodstream forms of *Trypanosoma brucei*. Here,
21 we report the evaluation of 20-deoxysalinomycin, a naturally occurring homolog to
22 salinomycin, for trypanocidal and cell swelling activity. The concentration of 20-
23 deoxysalinomycin required to reduce the growth rate of bloodstream-form trypanosomes by
24 50% was determined to be 0.12 μM and found to be 8 times more trypanocidal than
25 salinomycin. Moreover, 20-deoxysalinomycin and salinomycin displayed similar cytotoxic
26 activity against human HL-60 cells. Measured as the ratio of cytotoxic to trypanocidal activity,
27 20-deoxysalinomycin thus exhibit a four-fold higher selectivity compared to salinomycin. The
28 stronger trypanocidal activity of 20-deoxysalinomycin is attributed to an enhanced ability to
29 induce cell swelling in trypanosomes. The findings support 20-deoxysalinomycin as a useful
30 lead in the rational development of new and improved anti-trypanosomal drugs.

31

32 *Keywords*

33 African trypanosomiasis

34 *Trypanosoma brucei*

35 Polyether ionophores

36 20-Deoxysalinomycin

37

38 1. Introduction

39

40 African trypanosomiasis is a parasitic disease affecting both humans and livestock. The
41 disease is known as sleeping sickness in humans and nagana disease in animals and is caused
42 by protozoans belonging to the Salivarian group of the genus *Trypanosoma* (Steverding, 2008).
43 Restricted to sub-Saharan Africa, the geographical distribution of the disease correlates with
44 the spread of tsetse flies, which are the vectors for the parasites (Steverding, 2008). Both male
45 and female tsetse flies transmit trypanosomes to their mammalian host during blood feeding.
46 The disease causes severe illness in humans and livestock and is, without treatment, fatal in
47 most cases. Unfortunately, Only a few therapies are currently available for the treatment of
48 African trypanosomiasis. Most of these have limited efficacy and cause serious side effects
49 (Giordani et al., 2016; Steverding, 2017). Furthermore, drug resistance in African
50 trypanosomiasis is a growing problem, particularly in nagana disease (Delespaux and de
51 Koning, 2007; Giordani et al., 2016; Okello et al., 2022). Although the number of reported
52 cases of sleeping sickness has fallen significantly in recent years due to sustained control efforts
53 in affected regions (WHO, 2019), nagana disease remains a major problem in sub-Saharan
54 Africa with annual economic costs of US\$4.5 billion (Mattioli, 2016). One of the main
55 problems in animal trypanosomiasis is that the currently available treatments are becoming
56 increasingly ineffective (Giordani et al., 2016). New drugs for the treatment of this disease are
57 therefore much sought.

58 Polyether ionophore antibiotics have shown promising anti-proliferative activity against
59 several protozoan parasites including African trypanosomes (Antoszczak et al., 2019a). In
60 particular, the carboxylic polyether ionophore salinomycin and its derivatives have been
61 extensively investigated for their anti-trypanosomal activities (Steverding and Sexton, 2013;
62 Steverding et al., 2016; Antoszczak et al., 2019b; Czerwonka et al., 2021). In the course of
63 these studies, we have found that inverting the relative configuration of the C20 hydroxyl
64 group, situated on the salinomycin C-ring, reduces the trypanocidal activity (Czerwonka et al.,
65 2021). On the other hand, oxidation of the C20 into a keto function leads to an increase in
66 trypanocidal activity compared to the parent compound (Antoszczak et al., 2019b). In light of

67 these observations, it would be interesting to evaluate the trypanocidal activity of 20-
68 deoxysalinomycin (SY-1), a compound related to salinomycin that lacks its C20 hydroxyl
69 group (Fig. 1). 20-Deoxysalinomycin is an intermediate in the biosynthesis of salinomycin and
70 occurs as a minor product during the fermentation of *Streptomyces albus* ATCC 21838
71 (Westley et al., 1977; Miyazaki et al., 1978; Yurkovich et al., 2012). Until recently, 20-
72 deoxysalinomycin has not been readily available, but in 2014 a practical semi-synthesis
73 through a regioselective allylic radical-deoxygenation of salinomycin was reported (Huang et
74 al., 2014).

75 Here, we report on the trypanocidal and cytotoxic activity of 20-deoxysalinomycin using
76 bloodstream forms of *Trypanosoma brucei* and human myeloid HL-60 cells, respectively. The
77 effectiveness of the 20-deoxysalinomycin to induce cell swelling in trypanosomes is also
78 described and mechanistic implications are discussed.

79

80 **2. Materials and methods**

81

82 *2.1. Compounds*

83

84 20-Deoxysalinomycin sodium salt was prepared as previously described (Huang et al.,
85 2014). Salinomycin sodium salt was isolated from commercially available veterinary premix
86 SACOX[®] as previously described (Antoszczak et al., 2019b). Suramin sodium salt was
87 purchased from Fluka, Germany.

88

89 *2.2. Cell culture*

90

91 Bloodstream forms of *T. brucei* (clone 427-221a; Hirumi et al., 1980) and human myeloid
92 leukaemia HL-60 cells (Collins et al., 1977) were grown in Baltz medium (Baltz et al., 1985)
93 supplemented with 16.7% heat-inactivated bovine serum. The cultures were maintained in an
94 incubator in a humidified atmosphere containing 5% CO₂ at 37 °C.

95

96 2.3. *In vitro* cell toxicity assay

97

98 The anti-proliferate activity of 20-deoxysalinomycin, salinomycin, and suramin was
99 evaluated as previously described (Merschjohann et al., 2001) with some modifications. In
100 brief, cells (trypanosomes and HL-60 cells) were seeded in 96-well plates to a final volume of
101 200 μ l Baltz medium containing various concentrations of test compounds (tenfold dilution
102 from 100 μ M to 100 pM) and 0.9% DMSO. Wells containing medium and 0.9% DMSO served
103 as controls. The initial cell densities were 1×10^4 /ml for trypanosomes and 5×10^4 /ml for HL-
104 60 cells. After incubation for 24 h, 20 μ l of a 0.5 mM resazurin solution prepared in sterile PBS
105 was added and the cells were incubated for a further 48 h. Thereafter, the absorbance of wells
106 was read on a BioTek ELx808 microplate reader using a test wavelength of 570 nm and a
107 reference wavelength of 630 nm. The 50% growth inhibition (GI₅₀) value, i.e., the
108 concentration of a compound necessary to reduce the growth rate of cells by 50% compared to
109 the control, was determined using a 4-parameter logistic online curve calculator (AAT
110 Bioquest, 2022).

111

112 2.4. Cell swelling assay

113

114 Change in cell volume in flagellated protozoans can be measured by the light scattering
115 technique monitoring the absorbance of cell suspensions between 450 and 550 nm (Park et al.,
116 1977) whereby a decrease in absorbance corresponds to an increase in cell volume. Based on
117 the filter availability of the BioTek ELx808 microplate reader, changes in cell volume of
118 trypanosomes were determined at 490 nm as previously described (Steverding and Sexton,
119 2013). In brief, bloodstream-form trypanosomes were incubated at a density of 5×10^7 cells/ml
120 in 96-well plates in a final volume of 200 μ l Baltz medium containing 100 μ M ionophore and
121 0.9% DMSO (test) or 0.9% DMSO alone (control). The absorbance of the cultures was
122 measured every 10 min for 1 h. At the end of the experiment, cells were microscopically
123 checked for motility as an indicator of liveliness.

124

125 3. Results and discussion

126

127 20-Deoxysalinomycin showed a dose-dependent inhibitory effect on the growth of bloodstream
128 forms of *T. brucei* with a GI₅₀ value of 0.12 μM (Fig. 2a), and was found to be 8.3 times more
129 trypanocidal than the parent compound salinomycin (GI₅₀ = 1.00 μM (Fig. 2a)). On the other
130 hand, 20-deoxysalinomycin and salinomycin displayed similar cytotoxic activity toward
131 human HL-60 cells with GI₅₀ values of 3.1 μM and 6.2 μM, respectively (Fig. 2b). Thus, while
132 salinomycin showed only moderate selectivity with a GI₅₀ ratio of 6 (defined as the cytotoxic
133 to trypanocidal activity ratio), 20-deoxysalinomycin had a four-times higher GI₅₀ ratio of 26.
134 Furthermore, 20-deoxysalinomycin was only slightly less trypanocidal than suramin (GI₅₀ =
135 0.044 μM), one of the drugs currently used for the treatment of sleeping sickness (Fig. 2a).
136 However, suramin is nontoxic to human cells (GI₅₀ >100 μM). Thus, while the data highlights
137 20-deoxysalinomycin as having a superior selectivity compared to salinomycin, structural
138 analogues of this compound with stronger trypanocidal activity and further reduced
139 cytotoxicity remain an important pursuit.

140 The trypanocidal activity of polyether ionophore antibiotics is due to their ability to
141 mediate a sodium ion influx in trypanosomes, which in turn, leads to cell swelling (Steverding
142 and Sexton, 2013; Steverding et al., 2016; Steverding and Huczyński, 2017; Antoszczak et al.,
143 2019b; Czerwonka et al., 2021). In general, salinomycin derivatives with enhanced
144 trypanocidal activity also display increased ionophoretic activity when compared to the
145 unmodified parent compound (Steverding et al., 2016; Antoszczak et al., 2019b; Czerwonka et
146 al., 2021). Exceptions have however been reported (Antoszczak et al., 2019b). For example,
147 salinomycin derivatives modified at the C1-position combine enhanced antitrypanosomal
148 properties with reduced ionophoretic activity (Steverding et al., 2016; Antoszczak et al.,
149 2019b).

150 To gain insight into the factors underlying the activity differences between 20-
151 deoxysalinomycin and salinomycin, we sought to evaluate whether the enhanced trypanocidal
152 activity of 20-deoxysalinomycin was related to increased iontophoresis. Bloodstream forms of
153 *T. brucei* were therefore incubated with 20-deoxysalinomycin at 100 μM concentration. The

154 resulting swelling of the cells was initially similar to that of parasites treated with salinomycin
155 at the same concentration (Fig. 3). However, after 20 min incubation, the swelling induced by
156 20-deoxysalinomycin was more pronounced and by the end of the experiment, trypanosomes
157 incubated with 20-deoxysalinomycin had swollen 30% more compared to parasites exposed to
158 the parent compound (Fig. 3). It should be noted that at the end of the experiment, the
159 trypanosomes had lost their normal elongated shape and appeared as round cells; an effect
160 previously described for trypanosomes treated with salinomycin (Steverding and Sexton,
161 2013). Nevertheless, the trypanosomes were still alive as shown by minor movement. This
162 result indicates that the higher trypanocidal activity of 20-deoxysalinomycin compared to
163 salinomycin is indeed connected to a higher ionophoretic activity. The molecular level origin
164 for this difference is however not obvious. Structurally, the global conformation of salinomycin
165 is conserved in 20-deoxysalinomycin (Huang et al., 2014; Borgström et al., 2017). As for the
166 C20-hydroxyl group of salinomycin, it is involved in intramolecular hydrogen bonding, but not
167 metal coordination (Paulus et al., 1998). We interpret the higher ionophoretic activity of 20-
168 deoxysalinomycin as, at least in part, related to its higher lipophilicity leading to more facile
169 uptake in lipophilic environments like biological membranes (miLogP for 20-
170 deoxysalinomycin = 7.36, miLogP for salinomycin = 6.45; determined using the
171 Molinspiration interactive logP calculator (Molinspiration Cheminformatics, 2022)). However,
172 an additional contributor may be that the absence of a C20-hydroxyl group facilitates ion
173 transport by a faster capture-release mechanism of sodium ions for the deoxygenated structure
174 (Matsumori et al., 2007).

175 In summary, this study further supports our previous findings that derivatisation of
176 salinomycin is an efficient approach to developing compounds with increased trypanocidal
177 activity (Steverding et al., 2016; Antoszczak et al., 2019b). 20-Deoxysalinomycin, a natural
178 product, structurally related to salinomycin but lacking its hydroxyl group at the C20 position,
179 proved to be a promising trypanocidal compound being almost an order of magnitude more
180 effective and four times more selective than its parent compound when evaluated with
181 bloodstream-form trypanosomes *in vitro*. In addition, 20-deoxysalinomycin matches key
182 criteria for drug candidates against African trypanosomiasis ($GI_{50} < 0.2 \mu\text{g/ml}$, GI_{50} of 20-

183 deoxysalinomycin = 0.088 $\mu\text{g/ml}$; SI >100, SI of 20-deoxysalinomycin = 26 (Nkawa and
184 Hudson, 2006)). Going forward, it should be possible to further improve the trypanocidal
185 activity and drug properties of this lead, for instance, through modifications of the C1
186 carboxylate moiety (Steverding et al., 2016; Antoszczak et al., 2019b). Such studies are
187 underway in our laboratory and will be reported in due course.

188

189 **CRedit author statement**

190

191 **Dietmar Steverding:** Conceptualization, Methodology, Validation, Formal analysis,
192 Investigation, Data curation, Writing – Original draft, Visualization. **Daniel Strand:**
193 Methodology, Validation, Investigation, Recourses, Writing – Review and Editing, Funding
194 acquisition; **Adam Huczyński:** Conceptualization, Resources, Writing – Review and Editing.

195

196 **Acknowledgements**

197

198 Daniel Strand thanks The Swedish Cancer Foundation, The Crafoord Foundation, and the
199 Swedish Research Council for funding.

200

201 **Declaration of competing interest**

202

203 The authors declare that they have no conflict of interest.

204

205 **References**

206

207 AAT Bioquest, 2022. Quest Graph™ Four Parameter Logistic (4PL) Curve Calculator.

208 [https://www.aatbio.com/tools/four-parameter-logistic-4pl-curve-regression-online-](https://www.aatbio.com/tools/four-parameter-logistic-4pl-curve-regression-online-calculator)
209 [calculator](https://www.aatbio.com/tools/four-parameter-logistic-4pl-curve-regression-online-calculator) (assessed 16 July 2022).

210 Antoszczak, M., Steverding, D., Huczyński, A., 2019a. Anti-parasitic activity of polyether
211 ionophores. *Eur. J. Med. Chem.* 166, 32-47.

- 212 Antoszczak, M., Steverding, D., Sulik, M., Janczak, J., Huczyński, A., 2019b. Anti-
213 trypanosomal activity of doubly modified salinomycin derivatives. *Eur. J. Med. Chem.*
214 173, 90-98.
- 215 Baltz, T., Baltz, D., Giroud, C., Crockett, L., 1985. Cultivation in a semi-defined medium of
216 animal infective forms of *Trypanosoma brucei*, *T. equiperdum*, *T. evansi*, *T.*
217 *rhodesiense* and *T. gambiense*. *EMBO J.* 4, 1273-1277.
- 218 Borgström, B., Huang, X., Hegardt, C., Oredsson, S., Strand, D., 2017. Structure-activity
219 relationships in salinomycin: Cytotoxicity and phenotype selectivity of semi-synthetic
220 derivatives. *Chem. Eur. J.* 23, 2077-2083.
- 221 Collins, S.J., Gallo, R.C., Gallagher, R.E., 1977. Continuous growth and differentiation of
222 human myeloid leukaemic cells in suspension culture. *Nature* 270, 347-349.
- 223 Czerwonka, D., Barcelos, Y., Steverding, D., Cioch, A., Huczyński, A., Antoszczak, M.,
224 2021. Single and double modified analogues of C20-*epi*-salinomycin: A new group of
225 antiparasitic agents against *Trypanosoma brucei*. *Eur. J. Med. Chem.* 209, 112900.
- 226 Delespaux, V., de Koning, H.P., 2007. Drugs and drug resistance in African trypanosomiasis.
227 *Drug Resist. Updat.* 10, 30-50.
- 228 Giordani, F., Morrison, L.J., Rowan, T.G., de Koning, H.P., Barrett, M.P., 2016. The animal
229 trypanosomiasis and their chemotherapy: a review. *Parasitology* 143, 1862-1889.
- 230 Hirumi, H., Hirumi, K., Doyle, J.J., Cross, G.A.M., 1980. *In vitro* cloning of animal-infective
231 bloodstream forms of *Trypanosoma brucei*. *Parasitology* 80, 371-382.
- 232 Huang, X., Borgström, B., Månsson, L., Person, L., Oredsson, S., Hegardt, C., Strand, D.,
233 2014. Semisynthesis of SY-1 for investigation of breast cancer stem cell selectivity of
234 C-ring-modified salinomycin analogues. *ACS Chem. Biol.* 9, 1587-1594.
- 235 Matsumori, N., Morooka, A., Murata, M., 2007. Conformation and location of membrane-
236 bound salinomycin-sodium complex deduced from NMR in isotropic bicelles. *J. Am.*
237 *Chem. Soc.* 129, 14989-14995.
- 238 Mattioli, R.C., Cecchi, G., Paone, M., Herrero, R.A., Simarro, P.P., Priotto, G., Franco, J.R.,
239 2016. The programme against African trypanosomiasis. *EMPRES-Animal Health* 360 46, 9-
240 13.

- 241 Merschjohann, K., Sporer, F., Steverding, D., Wink, M., 2001. *In vitro* effect of alkaloids on
242 bloodstream forms of *Trypanosoma brucei* and *T. congolense*. *Planta Med.* 67, 623-
243 627.
- 244 Miyazaki, Y., Shibata, A., Tsuda, K., Kinashi, H., Ōtake, N., 1978. Isolation, characterization
245 and structure of SY-1 (20-deoxysalinomycin). *Agr. Biol. Chem.* 42, 2129-2132.
- 246 Molinspiration Cheminformatics, 2022. Interactive logP calculator.
247 <https://www.molinspiration.com/services/logp.html> (accessed 3 June 2022).
- 248 Nwaka, S., Hudson, A. (2006) Innovative lead discovery strategies for tropical diseases. *Nat.*
249 *Rev. Drug Discov.* 5, 941-955.
- 250 Okello, I., Mafie, E., Eastwood, G., Nzalawahe, J., Mboera, L.E.G., 2022. African animal
251 trypanosomiasis: A systematic review on prevalence, risk factors and drug resistance in
252 sub-Saharan Africa. *J. Med. Entomol.* 59, 1099-1143.
- 253 Park, J.-H., Schofield, P.J., Edwards, M.R. (1997) *Giardia intestinalis*: volume recovery in
254 response to cell swelling. *Exp. Parasitol.* 86, 19-28.
- 255 Paulus, E.F., Kurz, M., Matter, H., Vértesy, L., 1998. Solid-state and solution structure of the
256 salinomycin-sodium complex: Stabilization and different conformers for an ionophore
257 in different environments. *J. Am. Chem. Soc.* 120, 8209-8221.
- 258 Steverding, D., 2008. The history of African trypanosomiasis. *Parasit. Vectors* 1, 3.
- 259 Steverding, D., 2017. Sleeping sickness and nagana disease caused by *Trypanosoma brucei*,
260 in: Marcondes, C.B. (Ed), *Arthropod Borne Diseases*. Springer International
261 Publishing, Cham, pp. 277-297.
- 262 Steverding, D., Huczyński, A., 2017. *Trypanosoma brucei*: trypanocidal and cell swelling
263 activities of lasalocid acid. *Parasitol. Res.* 116, 3229-3233.
- 264 Steverding, D., Sexton, D.W., 2013. Trypanocidal activity of salinomycin is due to sodium
265 influx followed by cell swelling. *Parasit. Vectors* 6, 78.
- 266 Steverding, D., Antoszczak, M., Huczyński, A., 2016. *In vitro* activity of salinomycin and
267 monensin derivatives against *Trypanosoma brucei*. *Parasit. Vectors* 9, 409.

- 268 Westley, J.W., Blount, J.F., Evans, R.H. Jr., Liu, C.-M., 1977. C-17 epimers of deoxy-(O-8)-
269 salinomycin from *Streptomyces albus* (ATCC 21838). *J. Antibiot. (Tokyo)* 30, 610-
270 612.
- 271 WHO, 2019. WHO Interim Guidelines for the Treatment of Gambiense Human African
272 Trypanosomiasis. World Health Organization, Geneva.
- 273 Yurkovich, M.E., Tyrakis, P.A., Hong, H., Sun, Y., Samborsky, M., Kamiya, K., Leadlay,
274 P.F., 2012. Late-stage intermediate in salinomycin biosynthesis is revealed by specific
275 mutation in the biosynthetic gene cluster. *ChemBioChem* 13, 66-71.
- 276

277 **Figure legends**

278

279 **Fig. 1.** Structure of salinomycin sodium salt and 20-deoxysalinomycin sodium salt. The
280 PubChem Compound Identifier (CID) for salinomycin sodium salt and 20-deoxysalinomycin
281 sodium salt is 23703990 and 132577037, respectively.

282


283 **Fig. 2.** Effect of 20-deoxysalinomycin, salinomycin and suramin on the growth of bloodstream
284 forms of *T. brucei* and human myeloid leukaemia HL-60 cell. Trypanosomes (**A**) and HL-60
285 cells (**B**) were incubated with varying concentrations of 20-deoxysalinomycin (circles),
286 salinomycin (squares), or suramin (triangles). After 72 h of culture, cell viability and
287 proliferation were determined with the colourimetric dye resazurin. Mean values of the three
288 independent experiments are shown. Dose-response curves were calculated from mean values
289 using the 4-parameter logistic model. For clarity, standard deviations were omitted. The
290 standard deviations ranged between 0.6 and 13.4 percentage points.

291

292 **Fig. 3.** Effect of 20-deoxysalinomycin and salinomycin on the cell volume of bloodstream
293 forms of *T. brucei*. Trypanosomes (5×10^7 cells/ml) were incubated with 100 μ M 20-
294 deoxysalinomycin acid (open circles) or salinomycin (open squares) in Baltz medium in the
295 presence of 0.9% DMSO. Controls (closed diamonds) were incubated with 0.9% DMSO. Every
296 10 min, the absorbance at 490 nm was measured. For clarity, only the mean values of three
297 independent experiments are shown. The standard deviations ranged between 0.035 to 0.105.

298

299 **Fig. 1**
300




301
302

303 Fig. 2

304


305

A

306

307

308


B

309

310

311

312 **Fig. 3**
313



314
315

Highlights

- 20-deoxysalinomycin displays stronger trypanocidal activity than salinomycin.
- 20-deoxysalinomycin induces stronger cell swelling in trypanosomes than salinomycin.
- 20-deoxysalinomycin exhibits better selectivity than salinomycin.

Journal Pre-proof